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Abstract
The enzyme catechol-O-methyltransferase (COMT) has been shown to play a critical role in pain
perception by regulating levels of epinephrine (Epi) and norepinephrine (NE). Although the key
contribution of catecholamines to the perception of pain has been recognized for a long time, there
is a clear dichotomy of observations. More than a century of research has demonstrated that
increasing adrenergic transmission in the spinal cord decreases pain sensitivity in animals. Equally
abundant evidence demonstrates the opposite effect of adrenergic signaling in the peripheral
nervous system, where adrenergic signaling increases pain sensitivity. Viewing pain processing
within spinal and peripheral compartments and determining the directionality of adrenergic
signaling helps clarify the seemingly contradictory findings of the pain modulatory properties of
adrenergic receptor agonists and antagonists presented in other reviews. Available evidence
suggests that adrenergic signaling contributes to pain phenotypes through α 1/2 and β 2/3
receptors. While stimulation of α 2 adrenergic receptors seems to uniformly produce analgesia,
stimulation of α 1 or β receptors produces either analgesic or hyperalgesic effects. Establishing the
directionality of adrenergic receptor modulation of pain processing, and related COMT activity in
different pain models are needed to bring meaning to recent human molecular genetic findings.
This will enable the translation of current findings into meaningful clinical applications such as
diagnostic markers and novel therapeutic targets for complex human pain conditions.
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I. INTRODUCTION
COMT, a major metabolizing enzyme of catecholamines, has been strongly linked in several
pain models in both rodents and humans. Recently, our group discovered a functional
haplotype of murine Comt, the orthologous gene to COMT in humans and rats (termed
+SINE [1], ComtB2i [2], or the B allele [3]). Mouse strains of the ComtB2i haplotype have
increased enzymatic function [1]. Post-hoc analysis of inbred mouse data from the strain
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survey Heritability of Nociception series [4–6] confirmed the ComtB2i haplotype to be
genetically related to increased sensitivity to inflammatory conditions that evoke pain
behaviors [1]. In these assays, the subcutaneous application of irritants capsaicin, formalin
or bee venom elicited paw licking and/or shaking, and the administration of acetic acid or
magnesium sulfate injected intraperitonealy evoked abdominal writhing. Thermal assays
that show statistical significance effects included the hot plate and Hargreaves paw-
withdrawal assays (see [6] for experimental details).
These findings are in line with human genetic studies. In humans, high and low COMT
enzymatic activity haplotypes have been named accordingly with their association with
experimental pain sensitivity: The high activity haplotype is termed LPS for Low Pain
Sensitivity and the low activity haplotype is termed HPS for High Pain Sensitivity, Fig. (1)
[7]. Consistent with these observations, we also showed that the systemic suppression of
COMT activity, which increases catecholamine transmission, contributes to persistent pain
states via the stimulation of β2-and β3-adrenergic receptors [8].
A perplexing problem regarding the relationship between low levels of COMT activity with
clinical pain conditions and augmented sensitivity to noxious stimuli is the reported
antiallodynic effects mediated by the administration of COMT inhibitors in various animal
models [9–11]. While increasing adrenergic tone within the spinal cord is analgesic,
increasing adrenergic stimulation in anatomical regions remote to the spinal cord may either
increase or decrease pain processing in a manner that is stimulus modality dependent. From
current existing findings, it appears that COMT activity evokes opposite effects on
neuropathic pain and nociceptive/inflammatory pain: neuropathic pain is relieved by
increasing catecholamine stimulation of adrenergic receptors. Nociceptive and inflammatory
pain is relieved by decreasing catecholamine stimulation of adrenergic receptors in the
periphery and increasing catecholamine stimulation within the spinal cord.
For the purpose of this Review, we have adopted the description of pain etiology as
proposed by Scholtz and Woolf [12]. As such, the perception of pain can result from
nociceptive, inflammatory, or neuropathic origins. Using examples of neuropathic and
nociceptive pain we will present findings from animal and human studies that demonstrate
the regional specificity of catecholamine signaling. In this review we will not discuss the
effects of modulating of catecholamine signaling at supraspinal level. We will discuss
findings based on three means of increasing or decreasing catecholamine transmission
across pain modalities including 1) the examination of the effects of genetic background
(including strain specific, knock-out and transgenic animal studies); 2) the effects of direct
administration of catecholamines to peripheral and spinal sites; and 3) the effects of
pharmacological manipulation of distinct catecholamines pathways with α or β adrenergic
receptor agonists or antagonists. Table 1 lists agents or drugs discussed in this review.
II. NOCICEPTIVE PAIN
Nociceptive pain has as its primary biological function to warn an organism of impending or
immediate threat of tissue damage. The physiological underpinnings of nociceptive pain
have been extensively studied [13]. Nociceptive afferents (sensory neurons that convey
information to the central nervous system) are stimulated by diverse noxious physical
stimuli such a heat, cold, acid, and pressure [12]. These noxious stimuli activate sensory
afferents that transmit neuronal signals to the spinal cord which then engage a large
ascending and descending central nervous system network that shapes the sensory, affective,
autonomic and motor responses to the noxious stimuli [12].
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A. Effects of Genetic Background on Nociceptive Pain
Here we will discuss the genotypic effect of catecholamine metabolism by natural and
engineered COMT functional haplotypes in animals and humans (Fig. 1).
1. Genetic Contributions of Comt to Peripheral Nociceptive Pain in Animals—
Evidence exists for the contribution of COMT genotype catecholamine levels to pain
sensitivity in rat and mouse models. Comt knockout mice exhibit increased thermal pain
sensitivity while transgenic mice expressing human COMT are more resistant to thermal
pain [14]. Inbred strains of mice, which have a naturally occurring functional haplotype that
increases COMT activity, ComtB2i, show increased tolerance to noxious thermal and
chemical stimuli [1]. A positive correlation between nociceptive and inflammatory pain also
strongly suggests a positive correlation between high COMT activity and decreased pain
sensitivity to both types of stimuli that evoke pain.
Findings derived from various rat strains also show a correlation between high COMT
activity and resistance to chemically-induced pain. Inbred Lewis-Wistar rats have
approximately twice the COMT activity in liver lysates compared to inbred Fisher-344 rats,
suggesting that functional COMT polymorphisms are also present in rats [15]. Lewis rats
display decreased sensitivity to inflammatory pain (e.g., formalin test) [16]. Consistent with
pain behavior of inbred mouse strains of the elevated ComtB2i functional haplotype, Lewis
rats show much less formalinevoked pain behaviors than Fisher-344 rats, which have lower
COMT activity.
2. Genetic Contributions of COMT to Human Experimental Pain—A common
SNP in COMT, rs4680 (val158met), codes for the substitution of valine to methionine [17].
The met isoform of COMT shows less thermostability and activity in vitro [18–21]. Because
a low activity allele should presumably lead to decreased catecholamine metabolism, a
substantial number of genetic studies have attempted to link val158met to various diseases
and pain conditions. In the first experimental human study to link the val158met
polymorphism with pain perception, hypertonic saline was infusion into the masseter muscle
and pain measures were increased in individuals homozygous for the met allele
polymorphism [22].
However, subsequent studies that have attempted to correlate val158met polymorphisms
with pain susceptibility have yielded inconsistent results (reviews by [11, 23, 24]). Until
recently, no mechanistic explanation has been advanced that relates lower enzymatic activity
beyond the observation that reduced enzyme thermal stability is seen with the methionine
substitution. Our group was the first to show that in addition to the contribution of rs4680,
there are functional polymorphisms that constitute three major haplotypes in the human
population, as opposed to only two major haplotypes. The val allele of rs4680, a guanine
(G), encodes for the most and least efficient enzyme. When taking into account these three
haplotypes, individuals with LPS and HPS alleles can be separated so that an individual
homozygous for the high pain sensitivity allele, who genotypes G/G for the rs4680 val, is
not placed in the same genetic category as a person homozygous for the low pain sensitivity
allele, who also genotypes G/G for the rs4680 val allele. However, because the HPS
frequency in Caucasian populations is relatively rare [7], this confounding effect is generally
small.
In a recent review of the association of COMT polymorphisms with pain sensitivity, many
experimental pain studies have confirmed an association between increased pain sensitivity
with low COMT enzymatic based on the three functional haplotypes defined by Diatchenko
[for review see 11]. Studies which used these haplotypes have been successful in relating
COMT genotypes to aggregate measures of human pain sensitivity based on combined z-
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score measures of pressure pain thresholds, thermal pain thresholds, thermal tolerance,
repeated measures of heat stimuli, and ischemic pain thresholds and tolerance [7]. Absolute
measures of heat pain threshold and tolerance, repeated measures of heat stimuli, and
pressure pain threshold [25], acute muscle pain from exercise (COMT genotype X pain
catastrophizing scores) [26], or pain from exposure to a laser beam [27] have also been
associated with these three haplotypes.
3. Genetic Contributions of COMT to Human Musculoskeletal Pain Conditions
—For more than forty years, it has been known that reduced levels of COMT activity in the
periphery is associated with common musculoskeletal and orofacial pain conditions [28, 29].
Temporomandibular joint disorder, or TMD, is a painful condition of the
temporomandibular joint and surrounding muscles and has been associated with the local
production of inflammatory cytokines [30–33]. The low activity HPS allele has since been
linked to post-operative pain [34], an increased risk of developing TMD [7], and in a recent
case report, a TMD patient with high pain sensitivity was found to have a novel, non-
synonymous protein coding mutation within a critical region of COMT [35]. The clinical
severity of fibromyalgia, a condition of widespread musculoskelfetal pain without apparent
cause [36], has been correlated with the HPS haplotype in a Spanish cohort [37].
Even with the confounding variable of the rare HPS allele, low catecholamine metabolism
associated with the met allele correlates with many musculoskeletal conditions. There are
many more studies that have tested the genetic association with the val158met
polymorphism than studies that have based association on the three identified HPS, APS,
and LPS functional haplotypes. In general, it is consistently found that the low COMT
activity met allele is associated with a higher risk of developing a painful condition. Met
homozygotes also report an increased number of pressure points, and non-affected relatives
of Israeli patients with fibromyalgia had a reduced frequency of the met COMT allele [38].
Similarly, met homozygotes have been shown to be enriched in two Brazilian fibromyalgia
cohorts [39, 40], a Spanish fibromyalgia cohort [41], a Turkish cohort [42], and in an
American cohort, met homozygotes experienced more pain on days when pain
catastrophizing was higher compared to women with at least one val allele [43].
Other nociceptive pain conditions have been associated with the met allele. Osteoarthritis
pain, which is can be considered a nociceptive pain evoked by mechanical stimuli [13],
appears to be greater in Europeans with the low activity met allele [44]. In an Irish cohort,
the development of postoperative pain following tooth extraction is greatest in individuals
homozygous for the met allele [45]. Spanish women homozygous for the met allele also
have greater pressure pain sensitivity, higher fatigue, and neck pain after surgery for breast
cancer [46] and children homozygous for the met allele with chronic tension type headache
have longer headache histories and greater pressure pain sensitivity [47].
4. Spinally-Mediated Nociceptive Pain—The thermally mediated tail-flick reflex is
frequently used as a pain assessment assay that has been extensively used to study the
pharmacodynamic properties of analgesics in rodents [48]. However, the tail-flick is a
spinally-mediated reflex, which can occur following the transection of the spinal cord rostral
to the lumbar region [49]. Thus, agents administered to the spinal space that modifies this
reflex mediate the pharmacological effects at the spinal level. Other common thermal
nociceptive assays that are frequently used to assess pain behavior and the analgesic
properties of compounds are the hot plate and Hargreaves’ tests. Unlike the tail-flick test,
the behavioral endpoints (e.g., paw withdrawal to noxious heat) are dependent on more than
a spinal reflex. Indeed, much of the confounding or seemingly contradictory findings can be
explained by pointing out that the tail-flick is a spinally derived nociceptive response, and
pain responses derived from peripheral injuries (paw or gut) result from the integration of
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complex neural networks associated with sensory afferents, spinal and supraspinal pathways
[50]. This could be one explanation for the inverse effects of decreased catecholamine levels
with regards to the tail-flick assays. Moreover, tail-flick data is in agreement with pain
sensitivity by rodent strain (Fig. 2).
In classic inbred strains of mice, the latency to tail-flick is negatively correlated with COMT
enzymatic activity such that strains with high COMT activity, which likely translate into
lower levels of synaptic catecholamines, have shorter tail-flick latencies (i.e., more pain
sensitive) than strains with low catecholamine metabolism [1]. The same pattern of tail-flick
behavior is seen in the high COMT activity Lewis and low COMT activity Fisher rats: In
comparison to Fisher rats, Lewis rats are significantly more sensitive (i.e. have shorter tail-
flick latencies) and vocalize more during the procedure compared to Fisher rats [16]. A third
line of behavioral evidence to point to decreased sensitivity to tail-flick in low COMT
activity rodent strains is found in an engineered S-COMT-deficient mouse line. S-COMT-
deficient mice show no difference by sex or genotype in an array of nociceptive assays, with
the exception of female mice in the tail-flick test [51]. Tail-flick latencies are longer in
female S-COMT deficient mice compared to female wild-type mice [10, 11, 51]. This
finding is in agreement with our hypothesis that higher basal levels of catecholamines in a
genetically modified rodent will protect from spinally mediated pain.
B. Administration of Catecholamines in Nociceptive Pain
The majority of data on nociceptive pain and pharmacologic catecholamine manipulation of
nociceptive pain are from animal studies. To decrease adrenergic signaling, catecholamines
depleting agents or adrenergic antagonists are administered via drinking water or by
injection into various anatomical sites (see Table 2). COMT inhibitors or adrenergic agonists
are used both clinically and as pharmacological probes to stimulate adrenergic receptors and
downstream signaling pathways. Here we will discuss the nociceptive effects of injecting
Epi or NE locally into the spinal space (intrathecal administration) or to peripheral
compartments with limited or no access to the brain.
1. The Administration of Epi or NE to the Peripheral Compartments—Enhanced
pain sensitivity (behavioral signs of either allodynia or hyperalgesia as defined by IASP
[52]) is observed in various rodent pain assays in response to the administration of
catecholamines such as Epi and NE. The intradermal administration of NE produces
enhanced pain sensitivity to mechanical stimuli [53–55] and the intradermal administration
of Epi produces enhanced pain sensitivity to mechanical and thermal stimuli in rats [56– 61].
Despite the use of Epi and NE to produce enhanced pain sensitivity, Epi is a common
vasoconstrictor used in conjunction with numbing agents to concentrate injected local
analgesics. However, Epi is not used by itself for local anesthesia [62]. Healthy human
subjects report a mild, shortlasting pain following intradermal injections of Epi into the leg
[63], and in another report, the infusion of Epi by a catheter inserted into the elbow evoked a
slight increase in pain due to electrical stimulation and a decrease in heat pain tolerance in
healthy subjects [64]. Intradermal administrations of NE are also reported to be painful and
produce thermal hyperalgesia, particularly if the skin is previously sensitized [65–67].
Furthermore, endogenous high levels of NE and Epi have been correlated with stress and
pain in human subjects. High levels of NE, as determined by urinary NE excretion rate,
correlate with musculoskeletal pain and work stress in male subjects [68] and Epi and NE
levels are higher in female nurses reporting back pain and stressful work events [69].
2. The Spinal Application of Epi or NE—When administered intrathecally, Epi
produces analgesia in rats [70, 71] and increases nociceptive thresholds to noxious heat in
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spinally transected cats [72]. Intrathecal administration of NE also produces increases the
latency to response to noxious heat in both the hot plate and tail-flick assays [73–75] and to
noxious tail pinch [76]. The intrathecal administration of NE also produces a spinally
mediated analgesia in rats and cats [75]. Furthermore, Epi has long been commonly used
clinically to enhance spinal anesthesia in humans [77–79]; The epidural administration of
Epi prolongs the anesthetic effects of co-administered tetracaine or lidocaine [80, 81].
Another method to increase catecholamine levels within the spinal cord is to implant tissues
or cells that generate catecholamines. Transplantation of adrenal chromaffin tissue from the
adrenal glands of the rat [82] or cow [83] into the subarachnoid space of rat spinal cord
reduces thermal sensitivity compared to control animals. Conversely, depletion of spinal
cord NE by the intrathecal injections of neurotoxins results in a decrease in hot-plate
latencies [74] and produces hyperalgesia in the tail-flick assay [84].
C. Pharmacological Modulation of Catecholamines and Nociceptive Pain
1. Effects of Systemically Administered COMT Inhibitors and Catecholamine
Depleting Agents on Nociceptive Pain—COMT inhibitors increase catecholamine
signaling by decreasing the metabolism of catecholamines and the systemic administration
of these inhibitors have been shown to increase sensitivity to noxious stimuli in animal
models. In nociceptive and acute inflammatory pain, the systemic administration of COMT
inhibitors peripheral to the spinal cord produce pharmacodynamic effects that mimic those
produced by the peripheral administration of Epi and NE. The systemic administration of
COMT inhibitors to rats [7, 8] and mice [11] induce mechanical and thermal hyperalgesia.
These results are one more line of evidence of enhanced nociceptive pain sensitivity with
increased peripheral catecholamine levels. The opposite effect, decreased nociceptive pain
sensitivity, has been reported with catecholamine depleting agents.
Catecholamine signaling may be reduced by the removal or destruction of sympathetic nerve
terminals that release catecholamines. Thus, chloroform-induced hyperalgesia in rodents can
be prevented by surgical sympathectomy, or chemical sympathectomy with catecholamine
depleting agent 6-OHDA [53]. However, in contrast to this analgesic properties of 6-OHDA
[53], intrathecal injections of 6-OHDA produces hyperalgesia when assessed with n
nociceptive stimuli [84, 85]. The contrasting effects of 6-OHDA on nociceptive evoked pain
are in agreement with our hypothesis that enhanced catecholamine transmission in the spinal
cord is analgesic while enhanced transmission at the level of peripheral primary afferents is
hyperalgesic (Fig. 1). Adrenergic agonists and antagonists follow this general pattern.
3. Effects of Adrenergic Agonists and Antagonists in Nociceptive Pain—Five
major groups of adrenergic receptors have been identified: α1, α2, β1, β2, and β3, reviewed
by [86]. These receptors are G protein-coupled receptors, which bind extracellular
endogenous agonists NE and Epi, resulting in the activation of specific signal transduction
pathways. Fig. (2) shows the effects of adrenergic receptor ligands on nociceptive and
neuropathic pain. The general pattern observed is that the spinal cord activation of α1/2, or
β2/3 adrenergic receptors decrease pain sensitivity (Fig. 2). At sites remote from the spinal
cord, the effect depends on receptor subtype.
3.1. Adrenergic Agonists in Nociceptive Pain: As we have discussed previously,
increasing catecholamine levels outside of the spinal cord increase sensitivity to nociceptive
stimuli: α1-agonists applied systemically or cutaneously also increase pain sensitivity.
Cutaneous injections of the selective α1-agonist phenylephrine produce thermal
hyperalgesia in mice [87] and augment pain behaviors when co-injected with a ligand for
P2X3 in non-injured rats [88]. In healthy human participants, the cutaneous ionophoresis of
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the selective α1-agonist phenylephrine produces thermal hyperalgesia in normal skin [89]
and pain in mildly injured skin was attenuated by the α1- antagonist terazosin [90]. These
effects show stimulation of the α1 receptor to be similar to the effect of systemic,
intradermal or intrathecal NE.
While we have found only a few reports on the hyperalgesic effects of peripherally applied
α1 agonists, there is extensive literature on the analgesic properties of peripherally applied
α2 agonists [reviewed by 91; Fig. 2]. This analgesic effect of α2 agonists is blocked or
reversed by α2 antagonists [73, 74, 87, 92–98]. The opposing effects of α1-agonists, which
increase pain sensitivity outside of the spinal cord, and α2-agonists, which are analgesic,
exemplify an adrenergic receptor subtype specificity to pain transmission.
While α1 or α2 agonists may increase or decrease pain outside of the spinal cord, the
stimulation of both α-adrenergic receptors within the spinal cord decreases sensitivity to
multiple modalities of nociceptive pain. Intrathecally administered α2- adrenergic agonists
such as clonidine, dexmedetomidine, ST-91, tizanidine, and PT-31 [54] produce
antinociceptive effects to a variety of noxious stimuli [76, 74, 97, 99–103]. The α1-
adrenergic agonists phenylephrine [73, 75], oxymetazoline [73, 104, 105] and methoxamine
[74, 98] produce analgesia when applied intrathecally, although one study did not observe an
analgesic effect of methoxamine [97]. We have not been able to find references in the
literature of α2 agonists promoting nociception when applied peripherally or intrathecally.
Furthermore, in our search for effects of agonists in nociceptive pain, we found two reports
of a β- adrenergic agonist isoproterenol, which had no effect on nociception with intrathecal
application [75, 97], yet increased mechanical and ischemic pain in intradermal and
intravenous injections [56, 106] (Table 1).
3.2. Adrenergic Antagonists in Nociceptive Pain: Consistent with our hypothesis, the
intrathecal administration of α1 receptor antagonists produce increased pain sensitivity,
while administration of the α1 receptor antagonists to the peripheral sites remote to the
spinal cord is analgesic in the nociceptive models (Fig. 2). Selective α1-antagonists are
analgesic with intradermal or systemic application. Intra-arterial administration of the α1-
antagonist terazosin attenuates the enhanced response of C- fibers evoked by interdermal
injections of capsaicin in rat [107]. Intra-plantar injections of terazosin also inhibit the
hyperalgesia produced by a P2X3/P2X2/3 receptor agonist in rat [88] and in humans,
terazosin has been shown to relieve pain in patients with ureteral stents [108].
Intraperitoneal administration of the selective α1-antagonist prazosin reduces the number of
body writhes induced by acetic acid in rats [109], Conversely, intrathecal administration of
α1-antagonists prazosin and WB 4101 produces thermal hyperalgesia in rats assessed with
the tail flick assay [110], although several reports showed no effect of prazosin [74, 111,
112].
Consistent with the uniformly analgesic effects of intrathecal stimulation of either α1 or α2
receptors, the nonselective α-antagonists phentolamine increases sensitivity to noxious
thermal stimuli when administered intrathecaly (Fig. 2) [110, 112, 113]. Other nonselective
α-antagonists have no effect on baseline nociceptive threshold with intrathecal [73, 76, 112,
114] or intra-dermal [53, 114] administration. Generally, α-antagonists are used to
characterize the analgesic site of action of α1-agonists [74, 110, 114] or α2-agonists [73, 74,
98, 115]. However, it has been reported that the increased pain sensitivity induced by
chloroform lesions is abolished by the intradermal injection of phentolamine, a nonselective
α-antagonist, or by yohimbine, which is a relatively selective α2-antagonists [53]. The
analgesic-like behaviors produced with phentolamine can be explained by its ability to block
α1-receptors at peripheral sites remote to the spinal cord, which produce hyperalgesic
effects. The analgesic properties associated with yohimbine might result from the blockade
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of serotonin receptors [116–118]. Thus, overall stimulation of α2 adrenergic receptors
uniformly produce analgesia and antagonists of α2 receptors generally increase pain
sensitivity in nociceptive pain models.
Unlike α receptors antagonists, β-agonists and antagonists seem to show uniform effects in
nociceptive pain assays, although there is a paucity of findings of the effects of β-agonist on
nociceptive pain. In contrast, there are many reports of β-antagonists administered remotely
to the spinal cord, which is analgesic. Non-selective β-adrenergic receptor antagonists
significantly attenuate nociceptive pain. For example, intradermal pretreatment with
propranalol, a nonselective β-adrenergic antagonist, significantly attenuates epinephrine-
induced hyperalgesia [56]. Intraperitoneal administration of propranalol blocks visceral
nociception [109], and propranalol or combined β2- and β3-adrenergic receptor antagonists
block mechanical and thermal hyperalgesia associated with COMT enzyme inhibition [8].
Interperoneal administration of nadolol augments analgesia to thermal nociception [119] and
the selective β1- antagonist metoprolol has been reported to attenuate visceral nociception
[109]. Furthermore, systemically derived and administered Epi dependent hyperalgesia are
blocked by both the non-selective β-antagonist propranalol and selective β2- antagonist ICI
118, 551 [60]. There are two reports of the non-selective β- antagonist propranalol
administered intrathecally, (Fig. 2). Intrathecal propranalol prolonged spinal anesthesia
[120] in one report and had no effect in another [114]. Intrathecal administration of the β1-
agonist isoproterenol had no effect in three reports [73, 75, 97] and intradermal
administration increased pain sensitivity in two other reports [56, 106]. Taken together, in
nociceptive pain models, antagonism of β-receptors is analgesic. More research is needed to
confirm the hyperalgesic effect of β-receptor agonists in nociceptive pain models.
Consistent with the effect of adrenergic drugs in nociceptive animal pain assays, α2-agonists
and β2-antagonists produce analgesia in several human pain conditions. Thus, clinical pain
is reduced by the nonselective β-antagonist propranalol in patients with fibromyalgia [121,
122] and TMD [121, 123], and the α2 agonist clonidine is prescribed for a variety of pain
conditions [124]. Ischemic pain from angina is also antagonized following treatment with
selective β1-antagonists [125, 126].
III. NEUROPATHIC PAIN
Common diseases, injuries, and interventions can cause neuropathic pain as a result of
damaging somatosensory pathways in the central and/or peripheral nervous system [127].
Unlike nociceptive pain, there is no discernable role for protection or repair in response to
neuropathic pain; neuropathic pain results from nerve pathology and does not provide an
adaptive protective warning regarding potential injury [12].
Given the multiple etiologies and case definition of neuropathic pain, a concise literature
review on this topic is difficult [128]. Many painful conditions once considered neuropathic
have now been redefined under the term Complex Regional Pain Syndrome. Neuropathic
pain is distinguished from pain due to inflammation, musculoskeletal pain, and other types
of pain that develop secondary to neuroplastic changes and the progression of neurologic
disorders [13, 129–133]. Therefore our discussion of neuropathic pain will be limited to
animal models that employ nerve injury as the causative insult used to produce subsequent
behaviors that mimic human neuropathic pain states.
A. Genetic Background Effects on Neuropathic Pain
To date, there is very little data on the effect of COMT polymorphisms and function on the
development of neuropathic pain. Lewis rats, which have greater COMT activity than
Fisher-344 rats [15], express neuropathic pain behaviors for longer time periods and require
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longer recovery times following injury to the sciatic nerve when compared with Fisher-344
rats [134–136]. Mouse strains of the ComtB2i haplotype, which is associated with increased
COMT enzymatic activity, tend to show greater pain behaviors to nerve injury [1]. The only
published study to date examining the relationship of COMT val158met and neuropathic
pain in humans, found no correlation between COMT genotype and neuropathic pain [137].
B. The Effects of Catecholamines on Neuropathic Pain
To our knowledge there is no recent literature on the effects of spinal intrathecal injections
of Epi or NE on experimental models of neuropathic pain; however, we have found
numerous reports of spinal subarachnoid cavity adrenal chromaffin tissue grafts on
neuropathic pain.
Transecting the sciatic and saphenous nerves in rats produces autotomy, a self mutilation
behavior thought to reduce the perception of neuropathic pain [138]. Autotomy is reduced
by 63% in rats spinally implanted with adrenal medulla tissue [139]. Similarly, rats treated
with bovine chromaffin cell implants show reduced allodynia, hyperalgesia, and skin
temperature abnormalities and the intrathecal delivery of the non-selective α-adrenergic
receptor antagonist phentolamine partially attenuates these effects. Transplants of either
embryonic rat or neonatal cow immortalized chromaffin cells also attenuate cold allodynia,
and tactile and thermal hyperalgesia following chronic constriction in the rat [140]. More
recently, bovine or porcine sources of chromaffin tissue were compared for efficacy in a rat
following chronic constriction [141]. The authors found that transplants from porcine
sources reduced mechanical and cold allodynia while transplants from bovine sources
reduced only cold allodynia. The implantation of chromaffin cells from humans with renal
cancer attenuates cold allodynia in rats with sciatic nerve injury [142]. In sum, spinal
chromaffin transplants decrease neuropathic pain in a manner that is sensitive to antagonism
with adrenergic antagonists.
C. The Effects of Pharmacological Modulation of Catecholamines on Neuropathic Pain
Neuropathic pain is relieved by pharmacological approaches that modulate catecholamine
release, metabolism by COMT, and by treatments with α and β2 adrenergic receptor
agonists.
1. COMT Inhibition—The oral administration of the COMT inhibitor nitecapone reverses
the mechanical and thermal hyperalgesia observed in streptozotocin-induced diabetic rats
[9]. The effect of nitecapone on thermal and mechanical hyperalgesia is contrary to the
effects of systemically administered COMT inhibitors described above on both thermal and
mechanical pain sensitivity where COMT inhibition evokes a hyperalgesic response to both
mechanical and thermal pain [8]. However, this seemingly contradictory “analgesic effect”
also holds true for other neuropathic pain conditions evoked by nerve ligation [143] where
the intraperitoneal administration of the COMT inhibitor nitecapone reverses the mechanical
and cold allodynia produced by spinal nerve ligation. In addition, dorsal horn neuronal
responses, to nociceptive C-fiber stimulation is attenuated by the intravenous administration
of the COMT inhibitor OR486 [10]. Thus, these animal studies demonstrated that the
systemic inhibition of COMT, which presumably increases the bioavailability of
catecholamines, produces an analgesiclike effect in response to peripheral nerve damage
induced by injury or metabolic insults.
2. Adrenergic Agonists and Antagonists in Neuropathic Pain Models—A review
of the literature shows that non-selective α-adrenergic receptor stimulation appears to
contribute to neuropathic pain behaviors in a manner that mimics its effects on nociceptive
pain: analgesic responses when nonselective α- or α1- adrenergic receptors are blocked by
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antagonists in the periphery remote to the spinal cord (Fig. 2). For example, in rats with L5-
L6 spinal nerve ligations, the intraperitoneal administration of the non-selective α-
antagonist phentolamine reduce mechanical pain sensitivity [144, 145] and thermal
sensitivity [146]. Intravenous administration of phentolamine suppresses nociceptor
excitation, which is blocked by the selective α1- antagonist prazosin [147]. In human trials,
patients with sympathetically maintained pain (SMP) report reduced thermal and mechanical
sensitivity following the intravenous administration of phentolamine [148]; however
significant analgesia in response to intravenously administered phentolamine was not
observed in a later SMP clinical trail [149] or in a painful diabetic neuropathy trail [150].
Furthermore, the subcutaneous administration of the nonselective α-antagonist RS42206 has
no effect on thermal or mechanical sensitivity in sciatic nerve transected mice [151].
The effect of selective α1- adrenergic antagonist in neuropathic pain is similar to what is
observed in nociceptive pain, but the literature is limited (Fig. 2). Intraperitoneal
administration of the selective α1- antagonist prazosin [146, 152] and terazosin [144]
decreased thermal and mechanical allodynia in neuropathic rats. However, in another report,
intradermal administration of prazosin did not alleviate mechanical pain sensitivity in L5/L6
nerve ligated rats [153]. And, the selective α1- agonist phenylephrine enhances both
nociceptive pain sensitivity and neuropathic pain in patients with post-herpetic neuralgia,
although the cohort was very small (15 subjects) [154]. Decreased mechanical pain with
intrathecal administration of the α1- agonist, oxymetazoline, in L5/L6 nerve damaged rats
[115] has been reported; however, the preponderance of evidence shows α1- agonists to
have no effect following intrathecal administration [105, 115, 155, 156].
While the literature on intrathecal or systemic/cutaneous administration of α1- agonists in
neuropathic pain is incomplete, there is abundant literature on the analgesic affect of α2-
adrenergic receptor stimulation on neuropathic pain (Fig. 2). In L5-L6 nerve ligated rats,
intrathecal administration of the α2-agonist clonidine [95, 157], dexmedetomidine [92, 101,
115] fadolmidine [92], uinoxaline [115], radolmidine [101], and ST-91 [95, 115] reduced
pain responses to noxious mechanical or thermal stimulation. In sciatic nerve injured rats,
intrathecal clonidine [158] and tizanidine [159] reduce mechanical sensitivity and clonidine
reduces thermal nociception in a pertussis toxin model of murine neuropathic pain [105].
Cutaneous or perineural administration of α2-agonists are also analgesic in neuropathic pain.
In L5-L6 nerve ligated rats, subcutaneous injections of dexmedetomidine [92], or clonidine
[160] reduces pain sensitivity in response to noxious mechanical or thermal stimulation. In
sciatic nerve injured rats, subcutaneously administered dexmedetomidine [151] or
perineurally administered clonidine [158, 161–163] also reduce mechanical or thermal pain
sensitivity. In human experimental studies, patients with painful diabetic neuropathy [150]
or causalgia [63], show reduced thermal and mechanical sensitivity with a clonidine
transdermal patch.
Systemic or intradermal α2-agonists produce analgesia in neuropathic pain models while
intrathecal α2-antagonists have no effect [95] or increase thermal sensitivity in neuropathic
animals [164]. However, it has been also reported that the α2-antagonist yohimbine
produces analgesia in neuropathic pain patients [149]. It is not clear if the analgesic effects
of yohimbine are mediated by blocking α2-receptors because this compound also has effects
on serotonin receptors [116–118] and thus the observed analgesic effects could be mediated
by receptors other than α2-adrenergic receptors. Additionally, this study did not control for a
placebo effect, which is necessary as clinical trials of analgesics often associate with strong
responses to placebo, (for reviews, see [165]). In addition, the α2-antagonist SKF-86466
also produces analgesia in a rodent neuropathic pain model [146] but the site of action in
producing analgesia is unknown but may involve supraspinal structures [166]. In sum, our
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current knowledge points to the analgesic effects of α2-adrenergic stimulation in
neuropathic pain, just as occurs with nociceptive pain.
Findings regarding the role of β-adrenergic receptors in neuropathic pain are sparse. We did
not find reports that examined the effects of intrathecal administration of β-agonists or β-
antagonists on neuropathic pain. Systemic or cutaneous administrations of non-selective, or
selective β1 and β3-agonists have no effect on neuropathic pain. In contrast to the systemic
administration of β2-agonists on nociceptive models, in neuropathic pain models, systemic
β2 stimulation relieves pain [167]. Intraperitoneal injections of a variety of β2-agonists
suppress mechanical allodynia following sciatic nerve constriction [167, 168]. Both
intraperitoneal and intrathecal injections of the (β2-antagonist ICI 118,551 attenuate
analgesia conferred by β2-agonists following never injury, providing evidence of the
analgesic effects of β2-agonists on neuropathic pain [167].
A recent case study reported that the β2-agonist salbutamol, produces a beneficial effect in a
small cohort of neuropathic pain patients [169]. The authors noted that β2 adrenergic agonist
induced analgesia in neuropathic pain conditions seems to be contrary to the demonstrated
beneficial analgesic effects of β-adrenergic antagonists in treating musculoskeletal pain
conditions [169]. This statement falls in line with our theory that increased catecholamine
levels are analgesic in neuropathic pain and produce a hyperalgesia to nociceptive and
musculoskeletal pain.
CONCLUSIONS
In this Review, and to our knowledge, we are the first to compare and contrast the role of
peripheral and spinal adrenergic signaling in modulating nociceptive and neuropathic pain.
There appears to be a common adrenergic pain modulatory mechanism among vertebrate
animals (i.e., cat, dog, rat, mouse, monkey, and human; Table 2). We propose that there is a
fundamental difference in the effects of catecholamine transmission in spinal cord and
peripheral nervous system that signals nociceptive information from skeletal muscle and
skin (Fig. 1).
How then does one account for the contribution of catecholamines and COMT enzyme
activity to different etiological sources of pain evoking stimuli? It appears from the available
published data that neuropathic pain should be responsive to decreased catecholamine
metabolism and increased adrenergic-receptor stimulation. Nociceptive, inflammatory and
musculoskeletal pain in humans appears to be driven by peripheral adrenergic receptor
stimulation; reducing this stimulation by adrenergic antagonists is analgesic. Although both
adrenergic α1/2 and β2/3 receptors seem to contribute to pain-related adrenergic signaling,
COMT-dependent adrenergic signaling appears to be associated mostly with β2 receptors.
While stimulation of α2 adrenergic receptor seems to uniformly produce analgesic effect,
stimulation of α1 or β2 receptors may produce either analgesic or hyperalgesic effects (Fig.
2). We hypothesize that the fundamental difference between the contribution of COMT
activity to neuropathic and nociceptive, musculoskeletal and inflammatory pain is driven by
a β2- and possibly α1 receptors mediated “switch”. Further investigation of the directional
effects of adrenergic signaling on the modulation and transmission of pain evoking stimuli
resulting from multiple etiologies is needed to translate basic molecular genetic and
behavioral findings into meaningful clinical findings that impact the treatment of complex
human pain conditions.
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Fig. 1. Model of relationship between COMT activity alleles and pain sensitivity in different pain
modalities
a: COMT enzyme is depicted as “pacman” and Epi and NE as small black dots. High
COMT activity in human or mouse alleles or in rat strains is assumed to result in less
adrenergic signaling. b: Axis between neuropathic pain and nociceptive types of pain is
tilted by catecholamine signaling. c: Two models of catecholamine metabolism, with the
spinal cord colored to denote increasing or decreasing pain sensitivity. High COMT activity
is hypothesized to be a risk factor for neuropathic pain and low COMT activity is
hypothesized to be a risk factor for nociceptive pain.
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Fig. 2. Summary of Adrenergic Receptors in Neuropathic and Nociceptive types of Pain
Arrows pointing upwards indicate increased nociception, X indicates no change.
Agmat = agmatine; Atenol = atenolol; Bamb = bambuterol; Betaxo = betaxolol; BRL44 =
BRL44408; Clen = clenbuterol; Dex = dexmedetomidine; Fadol = fadolmidine; Feno =
fenotero; Form = formoterol; Isopre = isoprenaline; Medet = medetomidine; Meta =
metaproterenol; Meth = methoxamine; Oxym = oxymetazoline; Phenox =
phenoxybenzamine; Phento = phentolamine; Phenyl = phenylephrine; Procat = procaterol;
Propran = propranolol; Radol = radolmidine; Rito = ritodrine; RS422 = RS42206; Salb =
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salbutamol; Salm = salmetoral; Terb = terbutaline; Tizan = tizanidine; Uinox = uinoxaline;
WB-41= WB-4101.
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Table 1
List of Pharmacologic Agents to Modulate Catecholamine Signaling
Adrenergic Signaling Down ⇓ Adrenergic Signaling UP ⇑
Compound Type Examples Compound Type Examples
COMT Activator (None yet) COMT Inhibitors NitecaponeOR 486









Adrenergic Antagonists Adrenergic Agonists (effects similar to epinephrine)
    α1
Prazosin
Terazosin
    α1
Phenylephrine
Methoxamine
    α2
Atipamezole
Yohimbine
    α2
Clonidine
ST-91
    α2A BRL44408     β Bambuterol
    Non-selective α-adrenergic antagonist PhentolaminePhenoxybenzamine     β 1 and 2 Isoprenaline








    β2
ICI 118,551
Butoxamine
    β3 SR 592308
    Non-selective β-blocker PindololPropranalol
*
Legend: Clonidine decreases peripheral NE release [170].
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Table 2





Epi/NE releasing or blocking drug ↓ ↑
Epi/NE releasing cell or tissue transplant ↓ *
Adrenergic Agonist ↓ ↓↑**
Adrenergic Antagonist ↑ ↓↑**
Enzymatic COMT activity ↑ ↓
*
Legend: We have not been able to find in the literature a description of an Epi/NE releasing cell or tissue (chromaffin) transplanted other than the
subarachnoid space, the eye, or within regions of the brain.
**
The (α2-adrenergic signaling is generally analgesic and α1 and β-adrenergic signaling is hyperalgesic or analgesic, depending on pain modality.
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2013 July 01.
